综述:肝细胞癌的系统治疗
本文综述了PubMed近期文献及近期会议数据,梳理索拉非尼获批以来肝细胞癌系统治疗的演变,包括靶向治疗的成功与失败、免疫治疗进展及生物标志物需求;结论指出索拉非尼(一线)和瑞戈非尼(二线)已获批,纳武利尤单抗在美国获条件批准用于索拉非尼经治患者,仑伐替尼(一线)、卡博替尼和雷莫芦单抗(索拉非尼经治)在III期试验达到主要终点,可能很快加入治疗武器库。
要点
- 索拉非尼(一线)和瑞戈非尼(二线)已获批用于肝细胞癌。
- 纳武利尤单抗在美国获条件批准用于索拉非尼经治患者。
- 仑伐替尼(一线)、卡博替尼和雷莫芦单抗(索拉非尼经治)在III期试验达到主要终点。
核心结论
- 索拉非尼(一线)和瑞戈非尼(二线)已获批用于肝细胞癌,纳武利尤单抗在美国获条件批准用于索拉非尼经治患者。
- 仑伐替尼(一线)、卡博替尼和雷莫芦单抗(索拉非尼经治)在III期试验达到主要终点,可能很快加入治疗武器库。
研究设计与样本
- 综述,检索PubMed近期发表的 studies 及近期会议数据,主要检索词包括肝细胞癌、酪氨酸激酶抑制剂、免疫治疗、免疫检查点抑制剂、索拉非尼、瑞戈非尼、仑伐替尼、卡博替尼、雷莫芦单抗和纳武利尤单抗。
主要发现
- 自索拉非尼获批以来,多种药物在一线和二线治疗中失败,近十年后才有其他酪氨酸激酶抑制剂在III期试验中成功。
- 纳武利尤单抗在美国获条件批准用于索拉非尼经治患者。
- 仑伐替尼(一线)、卡博替尼和雷莫芦单抗(索拉非尼经治)在III期试验达到主要终点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the first- and second-line setting and it took almost another decade until further tyrosine kinase inhibitors succeeded in phase III trials. AIM: To summarise the evolving field of systemic therapy of hepatocellular carcinoma. METHODS: We reviewed recently published studies identified from PubMed and data presented at recent meetings. Main search terms included hepatocellular carcinoma, tyrosine kinase inhibitors, immunotherapy, immune checkpoint inhibitors, sorafenib, regorafenib, lenvatinib, cabozantinib, ramucirumab, and nivolumab. RESULTS: We discuss the evolution of targeted therapies since the approval of sorafenib including failures and recent advances. We also elaborate the unmet need of biomarkers to guide treatment decisions and discuss the emerging field of immunotherapy in hepatocellular carcinoma. CONCLUSIONS: The tyrosine kinase inhibitors sorafenib (first line) and regorafenib (second line) have been approved for hepatocellular carcinoma, and the immune checkpoint inhibitor nivolumab obtained conditional approval for sorafenib-experienced patients in the United States. With lenvatinib in the first line, and cabozantinib and ramucirumab in sorafenib-experienced patients, three more targeted therapies reached their primary endpoint in phase III trials and may soon be added to the treatment armamentarium.
引用
- Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018. PMID: 30039640. doi:10.1111/apt.14913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。